Related Experiment Videos
Controlling isolated systolic hypertension. No time to be complacent
1Cardiology Section, University of Chicago Pritzker School of Medicine, IL 60637, USA. wpentz@medicine.bsd.uchicago.edu
Insights
Isolated systolic hypertension (ISH) in older adults is common and a significant predictor of health risks. Treating ISH offers clear benefits, but requires careful medication management due to potential adverse effects in the elderly.
Area of Science:
- Gerontology
- Cardiovascular Medicine
- Pharmacology
Background:
- Isolated systolic hypertension (ISH) is the predominant hypertension type in the elderly.
- ISH is a stronger predictor of morbidity and mortality than diastolic blood pressure.
- Established evidence supports the therapeutic benefits of treating ISH.
Purpose of the Study:
- To review the management of isolated systolic hypertension in the elderly.
- To highlight the importance of careful patient evaluation before initiating treatment.
- To outline pharmacologic therapy principles and differential diagnoses for persistent hypertension.
Main Methods:
- Review of existing clinical trial data and therapeutic guidelines.
- Emphasis on cautious pharmacologic management in elderly patients.
- Discussion of diagnostic considerations for refractory hypertension.
Main Results:
- Treatment of ISH yields significant benefits in reducing adverse health outcomes.
- Elderly patients face a higher risk of medication-related adverse effects.
- Gradual dose titration and careful monitoring are crucial for effective and safe treatment.
Conclusions:
- Pharmacologic therapy for ISH in the elderly should commence with low doses and slow titration.
- Persistent hypertension after multiple medication trials necessitates investigation into secondary causes.
- Consideration of white coat hypertension, secondary hypertension, and pseudohypertension is vital.
Abstract:
Isolated systolic hypertension (ISH) is the most common form of hypertension in the elderly. It is an even better predictor of morbidity and mortality than is diastolic blood pressure. Several large trials have documented a clear benefit to treating ISH. Therapy should be initiated only after careful evaluation of the patient's overall medical status, because the elderly are at increased risk of adverse effects from medications. Pharmacologic therapy should be started at a low dose and increased slowly, if necessary. If hypertension is still present after the addition of two or three medications, a cause other than essential hypertension should be considered, such as white coat hypertension, secondary hypertension, or pseudohypertension.